Figure S11. in CLL through CD40CCD40L signaling, which enhances the maturation and activity of cytotoxic T cells and, consequently, the apoptotic response of CLL cells. The cytotoxic response is facilitated by a depletion of the anti-inflammatory cytokine interleukin 10, targeted by promotes the apoptotic death of CLL cells only when functional T cells are restored. Overall, our findings suggest that the reinstatement of in CLL cells could be an exploitable adjuvant therapeutic option for the treatment of CLL. decrease during disease progression in peripheral blood mononuclear cells (PBMCs) from CLL patients [17]. Moreover, in a CLL murine model, reduces the leukemic cell fraction [18]. and are also able to induce the death of primary CLL cells in vitro [19], and their expression similarly decreases during CLL progression [20]. We hypothesized that the low expression of and that occur in patients during CLL progression could be due to the impaired interactions between T and CLL cells. To this end, we tested whether, potentiating such interactions, the expression of and could be restored and whether restoring the expression of could promote cell-mediated immune response and apoptosis in CLL cells. 2. Results 2.1. Activated T Cells Increase the Expression of KIAA1819 miR-181b, miR-181a and miR-130a in CLL Cells To investigate whether the decreased expression of observed in CLL could reflect inefficacy of T cell activation, we co-cultured CLL cells with CD4+T cells from healthy donors, since T cells from CLL patients show pathological defects [2,21]. Resting T cells were activated using antibodies against CD2, CD3, and CD28 and co-cultured with purified primary CLL cells. CD95 expression was analyzed to control B cell activation upon T/B cell interaction [22] (Figure S1). The analysis of re-purified CLL cells after 4 or 24 h of incubation with activated allogenic T cells revealed significantly increased expression of and (= 0.0004, = 0.0315, and = 0.0011 respectively, Wilcoxon test) (Figure 1ACC). In a similar experiment conducted using PBMCs from CLL patients, we found that significantly increased in purified CLL cells after 24 or 48 h of PBMC activation (= 0.0391, = 0.0042, and = 0.0003 respectively, Wilcoxon test) (Figure 1DCF). Open in a separate window Figure 1 Exogenous activation of T cells increases and expression levels in Chronic Lymphocytic Leukemia (CLL) cells. (ACC) Relative gene expression values in purified CLL cells co-cultured with activated vs. non-activated T cells. Purified CLL cells were mixed with either non-activated or activated (by anti-CD2, -CD3, -CD28 antibodies) T cells (CD4+) from healthy donors (HD) at a T/B ratio of 1 1:1. After 4 and 24 h CLL were re-purified and assayed for gene expression. (DCF) Relative gene expression values in purified CLL cells isolated from activated TG 100713 or non-activated peripheral blood mononuclear cells (PBMCs) from CLL patients. PBMC were activated as described above and then cultured for an additional 24 or 48 h. Relative expression values were determined by RT-qPCR; miRNAs data were normalized to the endogenous references with the 2 2?ct method. For each patient, the relative expression of miRNAs was normalized to the level of non-activated TG 100713 sample. Data are TG 100713 presented as means SEM and technical replicates are shown for each sample as black dots (). expression in CLL cells (Figure TG 100713 S2), indicating that T cells from CLL patients retain the ability to up-regulate upon exogenous activation. To evaluate if and increased at the transcriptional level, we analyzed the expression of their pri-miRNAs in several cases. We found that in CLL cells, the and were controlled by exogenously activated CD4+T cells, both allogenic (= 0.0007 and = 0.0017 respectively, Wilcoxon test) (Figure 2A,B) and autologous (= 0.0186 and = 0.0029 respectively, Wilcoxon test) (Figure 2D,E). This was not the case for (Figure 2C,F). Open in a separate window Figure 2 Exogenous activation of T cells increases and expression levels in CLL cells. (ACC) Relative gene expression values in purified CLL cells co-cultured with activated vs. non-activated T cells. Purified CLL cells were mixed with either non-activated or activated (by anti-CD2, -CD3, -CD28 antibodies) T cells (CD4+) from healthy donors (THD) at a T/B ratio of 1 1:1. After 4 and 24 h CLL were re-purified and assayed for gene expression. (DCF) Relative gene expression values in purified CLL cells isolated from activated or non-activated PBMCs from CLL.